A novel genomic test currently in the testing phase in the United Kingdom offers a promising approach to detecting pancreatic cancer in its early stages. The test is specifically aimed at individuals recently diagnosed with type 2 diabetes,who are considered a high-risk group for developing the disease.Pancreatic cancer is a particularly deadly form of cancer, frequently enough diagnosed at advanced stages when treatment options are limited.

The blood test analyzes samples to identify markers indicative of pancreatic cancer. The disease is often difficult to detect early due to its vague and non-specific symptoms. The clinical study for the test was launched at the Southampton Cancer Clinical Study Unit. Preliminary data indicates that the test has a 68% accuracy in identifying patients with early-stage pancreatic cancer and a 97% accuracy in excluding cases without the disease.

The genomic test focuses on patients over 50 years old who have recently been diagnosed with type 2 diabetes, as well as those with a genetic predisposition or family history of pancreatic cancer.According to researchers, the onset of diabetes can sometimes mask or mimic the early symptoms of pancreatic cancer because the cancer can destroy insulin-producing cells, similar to what occurs in diabetes.

“It is a meaningful period for early detection research, with blood -based, breathing and urine tests, wich, if they prove effective in clinical studies, could save thousands of lives annually,” said Dr. Chris Macdonald.

Each year, approximately 10,500 people in the UK are diagnosed with pancreatic cancer, and only a small fraction survive beyond 10 years. “Our initial data show that the test can identify pancreatic cancer in stages I and II. We collaborate with the Clinical Studies Unit Research UK Southampton and with the NHS Southampton University Hospital in this innovative study, which could redefine how we detect and manage pancreatic cancer in high risk,” said Samuel Levy Scientific at the Clearnotote health biotechnology company, which has developed the test and funds the clinical study.

Dr. Chris Macdonald, Pancreatic Cancer UK research director, emphasized the importance of early detection, noting that “over 80% of pancreatic cancer patients are diagnosed too late to benefit from treatment.”

While the initial results are encouraging, further research is necessary to validate the test’s effectiveness before it can be widely implemented. Symptoms of pancreatic cancer can be subtle and easily overlooked, including jaundice, itchy skin, dark urine, loss of appetite, unexplained weight loss, fatigue, fever, nausea, vomiting, diarrhea, constipation, abdominal pain, and indigestion.